Janux Therapeutics (JANX) Change in Accured Expenses (2020 - 2026)

Janux Therapeutics (JANX) has reported Change in Accured Expenses for 7 consecutive years, with -$2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 217.07% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at $2.5 million (down 67.33% YoY), while the FY2025 annual figure was $6.3 million, up 42.11% from the prior year.
• Change in Accured Expenses improved to -$2.0 million in Q1 2026 per JANX's latest filing, from -$4.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.2 million in Q3 2025 and bottomed at -$4.5 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $715529.4 across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 605.87% — and 2024, when it tumbled 483.57%.
• Janux Therapeutics' Change in Accured Expenses stood at $1.0 million in 2022, then slumped by 57.61% to $426000.0 in 2023, then sank by 483.57% to -$1.6 million in 2024, then slumped by 176.38% to -$4.5 million in 2025, then surged by 55.05% to -$2.0 million in 2026.
• Business Quant data shows JANX's Change in Accured Expenses at -$2.0 million in Q1 2026, -$4.5 million in Q4 2025, and $6.2 million in Q3 2025.